Teprotumumab for thyroid eye disease and thyroid problems in adults
Observes how adults with active thyroid eye disease do after teprotumumab treatment.
Key facts
- Who runs it
- Walter Reed National Military Medical Center
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 12 May 2021
- Expected to end
- 12 Dec 2027
- Type of study
- Observational
- Treatments tested
- Teprotumumab Injection [Tepezza]
- Record updated
- 23 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with eye problems linked to autoimmune thyroid disease, such as Graves disease, who are to be treated with teprotumumab (Tepezza). Only DOD beneficiaries can join.
- Age
- 18 years or older
- Sex
- All
- Disease stage
- Active thyroid eye disease with bulging eyes, eye or eye-socket pain, double vision, or swelling or redness of the eyelids or eye socket.
Main reasons for not taking part
- Pressure on the optic nerve that needs urgent eye-socket surgery or external beam radiation
- Diabetes that is not under control, now or in the past
- Inflammatory bowel disease that is not under control, now or in the past
- Under 18 years of age
- Pregnant or trying to become pregnant
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- only DOD beneficiaries
- adult patients 18 years of age or older
- adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease
Who cannot take part
- Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation
- patients with a history of uncontrolled diabetes mellitus
- patients with a history/diagnosis of uncontrolled inflammatory bowel disease
- patients under age 18 years
- patients who are pregnant or trying to become pregnant
Where in United States
- Walter Reed National Military Medical CenterBethesda, United StatesContact: Thanh D Hoang, DOTaking people
About the trial
What the trial wants to find out
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
Treatments tested
- Teprotumumab Injection [Tepezza]
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
- Plain-language title
- Teprotumumab for thyroid eye disease and thyroid problems in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 23 February 2024